Compare FPI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | REPL |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 454.6M |
| IPO Year | 2013 | 2018 |
| Metric | FPI | REPL |
|---|---|---|
| Price | $10.87 | $14.87 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 502.8K | ★ 3.1M |
| Earning Date | 04-29-2026 | 05-21-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $52,178,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $133.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.21 | $1.50 |
| 52 Week High | $13.23 | $16.33 |
| Indicator | FPI | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 73.05 | 54.75 |
| Support Level | $10.77 | $13.81 |
| Resistance Level | $11.78 | $15.71 |
| Average True Range (ATR) | 0.22 | 0.79 |
| MACD | 0.05 | -0.21 |
| Stochastic Oscillator | 89.31 | 40.08 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.